Gilead gets strong FDA panel support for hepatitis C drug
This article was originally published in Scrip
Executive Summary
Gilead Sciences’ hepatitis C drug sofosbuvir should be approved to treat multiple forms of the virus, including the most common type in the US, a panel of FDA advisers unanimously agreed.